Microscopic lymph node tumor burden quantified by macroscopic dual-tracer molecular imaging

Area of Science:

• Oncology
• Molecular Imaging
• Biomedical Engineering

Background:

• Lymph node biopsy is crucial for cancer staging but causes morbidity and delays.
• Current molecular imaging faces challenges with variable tracer delivery and nonspecific uptake.
• Noninvasive methods are needed to reliably assess lymph node involvement in cancer.

Purpose of the Study:

• To develop and validate a noninvasive molecular imaging method for quantifying tumor burden in lymph nodes.
• To overcome limitations of conventional imaging by correcting for nonspecific tracer uptake.
• To improve the accuracy and sensitivity of detecting metastatic disease in lymph nodes.

Main Methods:

• A dual-tracer molecular imaging approach was developed, involving targeted and untargeted tracers.
• Nonspecific tracer uptake was corrected by injecting a second, untargeted tracer.
• The method was validated in an athymic mouse model of human breast cancer, targeting epidermal growth factor receptor.

Main Results:

• A significant correlation was observed between in vivo dual-tracer imaging and ex vivo measurements of tumor burden (r = 0.97, P < 0.01).
• The method achieved a sensitivity of approximately 200 cancer cells.
• This dual-tracer technique demonstrated higher sensitivity compared to conventional lymph node biopsy.

Conclusions:

• The dual-tracer molecular imaging method enables reliable quantification of lymph node tumor burden.
• This noninvasive approach offers a promising alternative to lymph node biopsy for cancer staging.
• The technique has the potential to enhance early detection and management of metastatic cancer.